source
- Agios halts sickle cell drug program after disappointing phase 2 resultsAgios announced it is stopping development of its next‑generation pyruvate kinase activator, tebapivat, for sickle cell disease after a phase 2 trial failed to meet expectations. The study enrolle…
- FDA issues warning letter to Alembic Pharmaceuticals over missing patient consent in clinical studyThe U.S. Food and Drug Administration sent a warning letter to Indian generic manufacturer Alembic Pharmaceuticals after it was found to have failed to obtain informed consent from participants in…